| PHN | paroxysmal noctural hemoglobinuria; passive Heymann nephritis; postherpetic neuralgia; public health... |
|---|---|
| TSA | technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso... |
| TSTA | toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen... |
| PHA | passive hemagglutination [test]; peripheral hyperalimentation; phenylalanine; phytohemagglutinin; ph... |
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| public sector | The area of a nation's economy that is tax-supported and under government control. (12 Dec 1998) |
|---|---|
| public utility commissions | State agencies that regulate investor-owned utilities operating in the state. (05 Dec 1998) |
| public utility district | (PUD) A publicly owned energy producer or distributor. PUDs operate as special government districts under the authority of elected commissions. They are not regulated by public utility commissions. (05 Dec 1998) |
| public utility regulatory policies act | (PURPA) A federal law requiring a utility to buy the power produced by a qualifying facility at a price equal to that which the utility would otherwise pay if it were to build its own power plant or buy power from another source. (05 Dec 1998) |
| hospitals, public | Hospitals controlled by various types of government, i.e., city, county, district, state or federal. (12 Dec 1998) |
| environment and public health | Natural and man-made environments and their impact on public health. (12 Dec 1998) |
| united states public health service | See: USPHS. (12 Dec 1998) |
| acetone-insoluble antigen | A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis. (18 Nov 1997) |
| allogeneic antigen | Genetic variations of the same antigens within a given species. (05 Mar 2000) |
| antigen | Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun. See: early gene. (18 Nov 1997) |
| antigen-antibody complex | The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble. Immune complexes activate complement through the classical pathway. See: glomerulonephritis, Arthus reaction, type III hypersensitivity. (12 Dec 1998) |
| antigen-antibody reaction | The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin. See: skin test. (05 Mar 2000) |
| antigen-binding site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
| antigen-combining site | See: paratope. (05 Mar 2000) |
| antigen excess | In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases. (05 Mar 2000) |